drugset / Trial / NCT00943566

A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer

NCT00943566

Phase 2 Withdrawn Labtec GmbH
RandomizedParallel-groupOpen-labelTreatment

Summary

The study hypothesis is that the safety and efficacy of sufentanil following transdermal application is comparable to sustained release morphine sulphate tablets in patients with chronic pain due to cancer.

Timeline

Start
2010-01
Primary completion
2010-12
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 400 mg
Subject Sufentanil Other / unclassified Other

Indications